Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
48-week versus 17-week trastuzumab in HER2-positive breast cancer
IRCT20250412065291N3Phase 3Completed
- Sponsor
- Ilam University of Medical Sciences
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind trial of trastuzumab in breast cancer (2 arms), sponsored by Ilam University of Medical Sciences. Primary endpoints: Overall survival and Disease-free survival. Started Oct 2025; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20250412065291N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250412065291N3.